JP Morgan slashes price target on Teva Pharmaceutical Industries Limited [TEVA] – find out why.

Teva Pharmaceutical Industries Limited [NYSE: TEVA] loss -2.36% or -0.22 points to close at $9.12 with a heavy trading volume of 7412788 shares. The company report on December 22, 2022 that Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023.

FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira® and confirmed that the data provided are sufficient to support a determination of interchangeability; approval requires satisfactory outcome of upcoming facility reinspection.

It opened the trading session at $9.19, the shares rose to $9.295 and dropped to $9.00, the range by which the price of stock traded the whole day. The daily chart for TEVA points out that the company has recorded 15.59% gains over the past six months. However, it is still -34.51% lower than its most recent low trading price.

If we look at the average trading volume of 9.09M shares, TEVA reached to a volume of 7412788 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Teva Pharmaceutical Industries Limited [TEVA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $9.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JP Morgan have made an estimate for Teva Pharmaceutical Industries Limited shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on November 14, 2022. The new note on the price target was released on November 04, 2022, representing the official price target for Teva Pharmaceutical Industries Limited stock. Previously, the target price had yet another raise to $10, while Jefferies analysts kept a Buy rating on TEVA stock. On August 05, 2022, analysts increased their price target for TEVA shares from 10 to 13.

The Average True Range (ATR) for Teva Pharmaceutical Industries Limited is set at 0.29, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 0.68. The Price to Book ratio for the last quarter was 1.16, with the Price to Cash per share for the same quarter was set at 1.96. Price to Free Cash Flow for TEVA in the course of the last twelve months was 20.14 with Quick ratio for the last quarter at 0.70.

Trading performance analysis for TEVA stock

Teva Pharmaceutical Industries Limited [TEVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.44. With this latest performance, TEVA shares gained by 3.99% in over the last four-week period, additionally plugging by 15.59% over the last 6 months – not to mention a rise of 15.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 54.99, with the RSI for the last a single of trading hit 55.39, and the three-weeks RSI is set at 54.15 for Teva Pharmaceutical Industries Limited [TEVA]. The present Moving Average for the last 50 days of trading for this stock 8.84, while it was recorded at 9.22 for the last single week of trading, and 8.74 for the last 200 days.

Teva Pharmaceutical Industries Limited [TEVA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Teva Pharmaceutical Industries Limited [TEVA] shares currently have an operating margin of +19.36 and a Gross Margin at +47.10. Teva Pharmaceutical Industries Limited’s Net Margin is presently recorded at +2.63.

Return on Total Capital for TEVA is now 8.67, given the latest momentum, and Return on Invested Capital for the company is 1.30. Return on Equity for this stock inclined to 4.20, with Return on Assets sitting at 0.87. When it comes to the capital structure of this company, Teva Pharmaceutical Industries Limited [TEVA] has a Total Debt to Total Equity ratio set at 229.31. Additionally, TEVA Total Debt to Total Capital is recorded at 69.63, with Total Debt to Total Assets ending up at 49.44. Long-Term Debt to Equity for the company is recorded at 214.37, with the Long-Term Debt to Total Capital now at 65.10.

Reflecting on the efficiency of the workforce at the company, Teva Pharmaceutical Industries Limited [TEVA] managed to generate an average of $35,884 per employee. Receivables Turnover for the company is 3.55 with a Total Asset Turnover recorded at a value of 0.33.Teva Pharmaceutical Industries Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.00.

Teva Pharmaceutical Industries Limited [TEVA]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva Pharmaceutical Industries Limited go to 2.00%.

An analysis of insider ownership at Teva Pharmaceutical Industries Limited [TEVA]

There are presently around $5,124 million, or 49.60% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 117,190,328, which is approximately 25.786% of the company’s market cap and around 1.88% of the total institutional ownership; BLACKROCK INC., holding 41,667,254 shares of the stock with an approximate value of $380.0 million in TEVA stocks shares; and CAPITAL WORLD INVESTORS, currently with $358.69 million in TEVA stock with ownership of nearly New of the company’s market capitalization.

Positions in Teva Pharmaceutical Industries Limited stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 174 institutional holders increased their position in Teva Pharmaceutical Industries Limited [NYSE:TEVA] by around 114,402,723 shares. Additionally, 208 investors decreased positions by around 65,055,372 shares, while 115 investors held positions by with 382,420,965 shares. The mentioned changes placed institutional holdings at 561,879,060 shares, according to the latest SEC report filing. TEVA stock had 41 new institutional investments in for a total of 53,486,702 shares, while 70 institutional investors sold positions of 20,518,377 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here